FDA Peptide Reclassification 2026: Which Peptides Are Coming Back
Summary
On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced that approximately 14 of 19 peptides previously restricted under the FDA’s Category 2 list would return to Category 1 status. This reverses a September 2023 decision that effectively banned compounding pharmacies from preparing widely used therapeutic peptides.
What’s Changing
- 14 peptides returning to legal compounding including BPC-157, TB-500, Thymosin Alpha-1, Ipamorelin, Selank, Semax, and GHK-Cu
- 5 peptides likely staying restricted including Melanotan II, GHRP-2, GHRP-6, LL-37, and PEG-MGF
- Category 1 means licensed compounding pharmacies can legally prepare these peptides under physician prescription
- This is NOT FDA approval — no peptide on this list has completed the clinical trial process required for drug approval
Current Status (March 30, 2026)
The FDA has not yet published its formal updated list. Kennedy’s announcement signals what is coming, but compounding pharmacies technically remain unauthorized to compound these substances until the official publication drops.
Check interactions between any of these peptides →
The 19 Peptides: Where They Stand
In September 2023, the FDA moved 19 peptides from Category 1 to Category 2 on its Bulk Drug Substances Under Evaluation list. The stated rationale: “immunogenicity risk, peptide-related impurities, and limited human safety data.”
The impact was immediate. Compounding pharmacies pulled these peptides from their shelves. Clinics that had built practices around peptide therapy lost access to their most prescribed compounds. Patients mid-protocol had their treatments interrupted. The gray market exploded.
Kennedy’s position on the original decision was blunt: “The Category 2 designations effectively created and accelerated the very gray market they were designed to prevent.”
Returning to Category 1 (Legal Compounding)
These peptides are expected to regain compounding eligibility:
| Peptide | Category | Research Status | Primary Use |
|---|---|---|---|
| BPC-157 | Healing | Extensively studied (preclinical) | Tissue repair, gut healing, inflammation |
| TB-500 | Healing | Well studied | Wound healing, muscle recovery |
| Thymosin Alpha-1 | Immune | Well studied | Immune modulation, approved in 35+ countries |
| AOD-9604 | Metabolic | Well studied | Fat metabolism, formerly TGA-approved in Australia |
| Ipamorelin | Growth Hormone | Well studied | GH secretion, body composition, sleep |
| CJC-1295 | Growth Hormone | Well studied | GH release (status contested — see below) |
| Selank | Cognitive | Well studied | Anxiety, cognitive function, approved in Russia |
| Semax | Cognitive | Well studied | Neuroprotection, approved in Russia/Ukraine |
| GHK-Cu | Skin/Healing | Well studied | Collagen synthesis, wound healing, hair growth |
| KPV | Immune | Emerging | Anti-inflammatory, gut inflammation |
| MOTS-c | Longevity | Well studied | Mitochondrial function, insulin sensitivity |
| Epitalon | Longevity | Well studied | Telomerase activation, pineal regulation |
| Kisspeptin-10 | Hormonal | Emerging | Reproductive hormone regulation |
| DSIP | Sleep | Emerging | Sleep architecture, stress response |
Likely Staying Restricted (Category 2)
Five peptides appear likely to remain on the restricted list due to safety concerns, misuse potential, or proximity to existing FDA-approved drug categories:
| Peptide | Concern | Details |
|---|---|---|
| Melanotan II | Cardiovascular + melanoma risk | Linked to nausea, blood pressure changes, and potential melanocyte stimulation raising skin cancer concerns |
| GHRP-2 | Complex side effects | Elevates cortisol and prolactin — unlike Ipamorelin which is selective for GH only |
| GHRP-6 | Complex side effects | Same cortisol/prolactin concerns as GHRP-2, plus significant appetite stimulation |
| LL-37 | Limited safety data | Antimicrobial peptide with very limited human safety data for systemic compounding use |
| PEG-MGF | Limited clinical evidence | PEGylated growth factor with minimal published human data |
Worth noting: Thymosin Alpha-1 has the strongest clinical backing of any peptide on this list. It’s approved as a prescription drug in over 35 countries for hepatitis B and C treatment and as an immune adjuvant. Selank and Semax are both approved pharmaceuticals in Russia. The Category 2 restriction on these compounds was always harder to justify than for something like PEG-MGF, which has almost no published human data.
What Category 1 Actually Means (and Doesn’t Mean)
The Category 1 vs Category 2 distinction controls whether compounding pharmacies can legally prepare a substance. That’s it. People are treating this announcement like the FDA just approved 14 new drugs. They didn’t.
Category 1 allows:
- Licensed compounding pharmacies (503A and 503B) to legally prepare the peptide
- Physicians to prescribe it through a compounding pharmacy
- Quality-controlled, pharmaceutical-grade preparations with certificates of analysis
- Regulatory oversight of the compounding process
Category 1 does NOT mean:
- FDA drug approval (that requires Phase I-III clinical trials, NDA submission, and years of review)
- Over-the-counter availability
- Insurance coverage (these remain cash-pay, typically $300-700 per compound)
- That the peptide has been proven safe and effective in rigorous human trials
- That “research use only” gray-market products are suddenly legitimate
The Gray Market Problem
Kennedy’s argument for reclassification had a pragmatic core: the Category 2 restrictions didn’t stop people from using these peptides. They just pushed demand underground.
When compounding pharmacies lost the ability to prepare BPC-157 and TB-500, patients didn’t stop wanting them. They turned to “research chemical” suppliers, overseas pharmacies, and unregulated online vendors selling peptides labeled “for research purposes only.” No physician oversight. No quality testing. No dosing guidance. No recourse if something went wrong.
The compounding pharmacy industry had quality controls: USP 797/795 compliance, PCAB accreditation, potency verification, sterility testing. The gray market has none of that. A 2024 analysis of gray-market peptide products found significant variability in actual peptide content versus label claims, contamination with bacterial endotoxins, and in some cases, entirely wrong compounds in the vial.
Reclassification to Category 1 doesn’t validate these peptides as proven treatments. It does restore the regulated supply chain that provides basic quality assurance.
The Supplement Angle
A separate but related push is happening simultaneously. On March 27, 2026, multiple outlets reported that dietary supplement manufacturers are lobbying the FDA to classify certain peptides as dietary supplement ingredients under the Dietary Supplement Health and Education Act (DSHEA).
This is a different regulatory pathway entirely. DSHEA allows supplement companies to sell products without pre-market approval as long as they don’t make drug claims. If peptides like BPC-157 were classified as dietary supplements, they could be sold over the counter without a prescription.
The peptide therapy community is split on this. Proponents argue it would dramatically increase access. Critics argue it would remove the physician oversight that makes peptide therapy reasonably safe, and that supplement-grade manufacturing doesn’t meet the purity standards needed for injectable compounds.
For now, the reclassification and the supplement push are separate tracks. Category 1 status restores the physician-prescription-plus-compounding-pharmacy model. The supplement pathway would bypass that model entirely.
What This Means If You’re Considering Peptide Therapy
If you’ve been using gray-market peptides, reclassification gives you a better option. Once the formal FDA publication drops:
- Find a physician who prescribes peptide therapy. Telehealth peptide clinics exist in most states
- Get bloodwork first. Baseline labs before starting any peptide protocol. The interaction checker can flag potential conflicts with other compounds you’re using
- Use a licensed compounding pharmacy — specifically one that’s PCAB-accredited and FDA-registered. They’ll provide certificates of analysis verifying potency and sterility
- Expect to pay out of pocket. Insurance doesn’t cover compounded peptides. Typical costs run $300-700 per compound depending on the peptide and pharmacy
If you’ve been waiting for legal access before trying peptides, this is the pathway. Not the gray market. Not “research chemical” vendors. A licensed physician and a regulated pharmacy.
Timeline and What to Watch
| Date | Event |
|---|---|
| September 29, 2023 | FDA moves 19 peptides to Category 2, restricting compounding |
| 2024 | Gray market explodes; compounding pharmacy industry pushes back |
| February 27, 2026 | HHS Secretary Kennedy announces reclassification on Joe Rogan Experience #2461 |
| March 2026 | Formal FDA publication expected but not yet released |
| TBD | Official Category 1 reinstatement takes effect |
The gap between announcement and implementation matters. Until the FDA actually publishes the updated list, compounding pharmacies cannot legally resume production. Kennedy said “within a couple of weeks” on February 27. It’s now March 30. The publication is overdue but reportedly still in process.
When it drops, expect a rush. Compounding pharmacies will need time to source raw materials, validate batches, and restart production. Don’t expect instant availability.
Frequently Asked Questions
Is BPC-157 legal again in 2026?
Not yet. HHS Secretary Kennedy announced that BPC-157 will return to Category 1 status, allowing licensed compounding pharmacies to legally prepare it under physician prescription. The formal FDA publication hasn’t been released as of March 30, 2026. Once published, BPC-157 will be legally accessible through compounding pharmacies but will still require a prescription.
Which peptides are staying banned?
Approximately 5 peptides are expected to remain on Category 2: Melanotan II (melanoma and cardiovascular concerns), GHRP-2 and GHRP-6 (cortisol and prolactin elevation), LL-37 (limited human safety data), and PEG-MGF (minimal clinical evidence). The CJC-1295 status is disputed between sources.
Can I buy peptides over the counter after reclassification?
No. Category 1 status means compounding pharmacies can prepare these peptides with a valid physician prescription. It does not mean over-the-counter availability. A separate push by supplement manufacturers to classify peptides under DSHEA could eventually allow OTC sales, but that’s a different regulatory track.
Are compounded peptides as good as pharmaceutical-grade drugs?
Compounding pharmacies operating under USP 797/795 standards produce pharmaceutical-grade preparations with potency and sterility testing. They are subject to state pharmacy board oversight and, for 503B outsourcing facilities, FDA inspection. This is significantly better than gray-market “research chemical” products, but compounded drugs have not undergone the same clinical trial process as FDA-approved drugs.
What should I do right now?
Wait for the formal FDA publication before seeking these peptides from compounding pharmacies. In the meantime, find a physician familiar with peptide therapy, get baseline bloodwork, and use the interaction checker to evaluate any stack you’re considering. When access resumes, you’ll have a provider relationship and lab baseline in place.
